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1116 (71.8%) non-CCB users (249±84 vs. 229±84, p<0.001). Patients with CCBs
showed more unfavorable baseline characteristics such as old age, hypertension,
dyslipidemia, chronic kidney disease, higher body mass index. The genotyping of
CYP3A4 (IVS10+12G/A) was successful in 1259 patients, and its distribution was
61.3%, 32.9% and 3.9% for GG, GA and AA-genotypes, respectively. After adjustment
for possible confounding factors, the number of A allele was associated with increased
vulnerability to CCB use (Effect of CCB use PRU-difference: +11 PRU, p=0.088, +19
PRU, p=0.038, +42 PRU, p=0.051, for patients with 0, 1, and 2 A alleles, respectively,
+20 PRU, p=0.020 for GA/AA genotypes). Using a defined cutoff value for high OPR,
only in the GA/AA genotypes did CCB use result in significantly increased risk for
high OPR (OR 1.70, 95% CI 1.09-2.64, p=0.018).
Conclusion: CCB use is associated with increased OPR. The number of CYP3A4
(IVS10+12G/A) A-allele may be associated with an increased vulnerability to the
effects of CCBs on clopidogrel response variation.
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Simpson1, John Morgan1, 2, Nick Curzen1, 2
1Wessex Cardiothoracic Unit, Southampton University Hospital, Southampton,
United Kingdom; 2University of Southampton School of Medicine, Southampton,
United Kingdom; 3The William Harvey Research Institute, Barts and the London
School of Medicine and Dentistry, London, United Kingdom
Background: The optimal duration of clopidogrel, particularly following DES,
remains contentious. Previous studies have observed a clustering of adverse events, in
particular stent thrombosis (ST), 1 year after clopidogrel cessation in DES. It has been
suggested that this may be due to a pro-thrombotic and/or pro-inflammatory response.
We investigated the effect of clopidogrel cessation on platelet reactivity and markers
of vascular inflammation in DES patients.
Methods: 33 patients on dual antiplatelet therapy and due to stop clopidogrel at 1 year
following DES were investigated. Venesection was performed at 4wks and 24hrs before
and 24hrs, 48hrs, 1, 2 and 4wks after clopidogrel cessation. At each time-point: (i)
ADP- and AA-induced platelet reactivity were measured using a simple, rapid, near-
patient platelet function test known as short Thrombelastography (s-TEG) that has
been developed and validated by this group; (ii) inflammatory biomarkers IL-6,
sCD40L and hSCRP were measured, and (iii) serum thromboxane B2 (TXB2) levels
were measured to assess the efficacy of aspirin.
Results: Following clopidogrel withdrawal, there was (i) a predictable increase in
ADP- and an unexpected and significant rise in AA-induced platelet aggregation (ii) a
significant decline in IL-6 and hsCRP at 1wk (p=0.006) and 4wks (p=0.003)
respectively. TXB2 was consistently suppressed confirming inhibition of COX-1 by
aspirin.
Increase in ADP- and AA-induced platelet aggregation following clopidogrel
cessation measured using s-TEG (AUC15 – area under the curve at 15 minutes;
Error bars represent mean+/-95%CI)
Conclusion: We have described for the first time an aspirin-independent time-
dependent increase in AA-induced clotting following clopidogrel cessation in DES.
As well as potentially helping to explain the clustering of ST events observed early
after withdrawal of long term clopidogrel, these findings raise important questions:(i)
should clopidogrel be tapered rather than abruptly withdrawn at 1 year? (ii) should we
discontinue aspirin instead of clopidogrel at 1 year? and (iii) is AA-induced clotting
an appropriate test of aspirin sensitivity? These findings demand further investigation.
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Genetic Determinants of Clopidogrel Responsiveness in Koreans
Jin Joo Park, Kyung Woo Park, Jeehoon Kang, Ki-Hyun Jeon, Si-Hyuk Kang, Hyo
Suk Ahn, Han-Mo Yang, Hae-Young Lee, Hyun-Jae Kang, Bon-Kwon Koo, Byung-
Hee Oh, Young-Bae Park, Hyo-Soo Kim
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Background: Activities of genetically regulated cytochrome enzymes, drug
transporters, and paraoxonase have been postulated to be associated with clopidogrel
response variability. However, controversy exists regarding which genetic variations
influence the antiplatelet effect of clopidogrel.
Methods: Clopidogrel on-treatment platelet reactivity (OPR) was measured and
genotyping of CYP1A2*1F, CYP2B6*6, CYP2C19*2, CYP2C19*3, CYP2C19*17,
CYP3A4 (IVS10+12G/A), CYP3A5*3, ABCB1 C3435T, and PON-1 Q192R was
performed in 1555 consecutive patients who underwent percutaneous coronary
intervention at Seoul National University Hospital.
Results: The mean OPR of the entire population was 235±84 (P2Y12 Reaction Units,
PRU). Genotyping results were available in 1299 patients. As for CYP2C19, 528
patients (40.8%) had no loss-of-function (LOF) allele, 629 patients (40.8%) 1 LOF-
allele and 137 patients (8.7%) 2 LOF-alleles. After adjustment for possible
confounders, each LOF-allele was associated with an OPR increase of 25 PRU (+25
PRU for 1 LOF, p=0.001, +52 PRU for 2 LOF-alleles, p<0.001). Genetic variations of
CYP1A2, 2B6, 3A4, and 3A5, as well as ABCB1 and PON-1 genes were not associated
with clopidogrel response variability. Using a defined cut-off value for high OPR, only
the CYP2C19 genotype was an independent predictor of high-OPR (OR 1.93, 95% CI
1.60-2.33, p<0.001). In subgroup analysis, among patients with 2 LOF-alleles of
CYP2C19, there was a further increase of OPR in the CYP3A4 (IVS10+12G/A)
GA/AA versus GG genotypes (288±10 PRU vs. 256±8.4 PRU, p=0.019).
Conclusion: Among genes postulated to be involved in clopidogrel metabolism, only
the CYP2C19 genotype is associated with response variability. PON-1 and ABCB1
genetic variants did not affect clopidogrel OPR.
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”Safety of Dual Antiplatelet Therapy in Patients Treated with Coronary Drug
Eluting Stents.”
Andrzej Drewnicki, Maciej Lesiak, Malgorzata Pyda, Marek Grygier, Wlodzimierz
Skorupski, Aleksander Araszkiewicz, Przemyslaw Mitkowski, Stefan Grajek
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Background: Numerous studies have shown the benefits of dual antiplatelet therapy
(DAT) in patients undergoing percutaneous coronary interventions (PCI) with drug
eluting stent (DES) implantation. The main benefit is a decrease in stent thrombosis
(ST) incidence, and, hence, in myocardial infarctions (MIs) and deaths. Nevertheless,
prolonged DAT is related to a greater incidence of bleeding complications. The optimal
length of DAT is yet to be determined. The study aims to assess long-term safety of
DAT in patients with coronary artery disease treated with DES.
Methods: The study group consisted of 500 patients with at least one DES.152 patients
received zotarolimus eluting stents, while 348 everolimus eluting stents. The mean
time of observation was 15.8 months (474 days). All patients received ASA 75mg in
combination with clopidogrel 75mg for at least 12 months. The patients were followed
up during hospitalization, and then after 1, 6, 12, 24, 36 months following the index
procedure. The primary endpoint concerned the rate of any bleeding complications,
defined according to the modified Global Use of Strategies to Open Occluded Coronary
Arteries (GUSTO) scale as severe/life threatening or as moderate bleedings without
hemodynamic compromise within the first 12 months after the index procedure.
Results: The population under study presented numerous risk factors of cardiovascular
disease.The patients’ mean age was 63.0±9.6 years, 362 patients were males (72.4%),
269 (53.8%) had a history of MI, 377 (75.4%) were hypertensive, 142 (28.4%) were
diabetic, 50 (10.0%) had peripheral artery disease and 24 (4.8%) had renal failure.
During long-term observation, bleeding complications occurred in only 14 patients
(2.8%). In 4 cases (0.8%), severe/life threatening bleeding was observed, and in another
10 cases (2.0%) a moderate bleeding occurred. Most bleedings - 12 (2.4%) - occurred
within the first 12 months of observation.
Conclusion: Severe/moderate bleeding is not a very common complication in patients
on prolonged DAT. An analysis of multiple risk factors of this complication will be
supplemented later.
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and agreement between two “point of care: VerifyNow®Aspirin assay and PFA-
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Background: Not all patients have the same response to the inhibitory effect of platelet
aggregation mediated by aspirin (ASA). Patients with diabetes mellitus are
characterized by enhanced platelet reactivity and a reduced response to oral antiplatelet
medications. Objectives:1) To determine the prevalence of hyporesponsiveness (HR)
to ASA in type 2 diabetic patients (DM) treated with percutaneous coronary
intervention (PCI) using drug-eluting stent and dual antiplatelet therapy using two
methods of measurement of antiplatelet,VerifyNow® Aspirin Assay (Accumetrics )
(VN) and platelet function analyser PFA-100® (Dade-Behring) (PFA). 2) To analyse
the correlation of the results obtained by both methods.
Methods: Patients DM were included with non−ST-segment elevation acute coronary
syndrome who underwent PCI and Xience V stent. After PCI the in vitro response to
antiplatelet therapy measured by ASA was determined, using the platelet function tests
VN and by the (PFA). The degree of correlation between both methods was determined
by calculating the Spearman correlation coefficient (rs) and the concordance with the
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kappa index.
Results: 100 patients were analysed. With the VN 7% of patients were HR to ASA
(ARU> 550) and 41% to PFA (TO <193S). 3% were HR to aspirin with both methods.
4% were HR to ASA with the VN system but sensitive to it with the analyser PFA.
38% were sensitive to ASA with the VN test and HR with the PFA and 55% were ASA
sensitive with both methods. The Spearman correlation coefficient between both
methods of measurement of was r2= 0.09 (p = 0.35) and the Kappa index value =
0.0062 (p = 0.91).
Conclusion: 1. The prevalence of HR to ASA in type 2 diabetic patients treated with
PCI using XienceV drug-eluting stent implantation and dual antiplatelet therapy is
highly variable depending on the measurement method used. 2. There is no
concordance or correlation between both methods of measurement, and therefore its
use should be restricted to clinical research, limiting the application of these tests in
clinical practice.
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Inhibition of Platelet Aggregation by Prostaglandin E1 (PGE1) May Be
Attenuated in Diabetic Patients During Therapy with Clopidogrel
Rolf P Kreutz, Perry Nystrom, Yvonne Kreutz, Jiao Miao, Richard Kovacs, David
Flockhart, Zeruesenay Desta, Yan Jin
Indiana University School of Medicine, Indianapolis, IN
Background: Diabetes mellitus (DM) is associated with increased platelet activation
and reduced platelet inhibition by clopidogrel. PGE1 increases adenyl cyclase activity
in platelets and increases cyclic AMP concentrations. PGE1 is an endogenous platelet
inhibitor and its effects are additive to exogenous P2Y12 inhibition. The VerifyNow
(VN) P2Y12 point of care assay includes PGE1 at 22nM to suppress P2Y1 receptor
signaling along with ADP.
Methods: Subjects with established coronary artery disease and prior coronary stenting
who were taking clopidogrel 75mg daily for >14 days were enrolled (n=96). Diabetic
(n=34) were compared with non-diabetic subjects (n=62). Light transmittance
aggregometry (LTA) was performed at various concentrations of ADP with and without
the addition of PGE1, as well as VN P2Y12 assay.
Results: Residual on-treatment platelet aggregation induced by 5, 10, and 20μM ADP
was not significantly different between subjects with and without DM. Addition of
22nM and 88nM PGE1 to 20μM ADP resulted in a significant reduction of maximal
platelet aggregation (MPA). Residual platelet aggregation with PGE1 was significantly
higher in subjects with DM as compared to non-diabetics. VerifyNow P2Y12 PRU was
higher in subjects with DM as compared to non-diabetics (table). VN P2Y12 reactivity
correlated with MPA induced by ADP 20μM (r=0.69) and ADP 20μM & PGE1 22nM
(r=0.61)
Conclusion: Addition of PGE1 to ADP was associated with higher residual MPA in
subjects with DM as compared to non-diabetics. On treatment MPA induced by ADP
alone was not significantly different between subjects with and without DM measured
by LTA. Addition of PGE1 to ADP agonist platelet assays may result in a higher
proportion of subjects with DM being classified as non-responders. Impaired inhibitory
response to PGE1 may contribute to the high platelet reactivity phenotype in subjects
with DM.
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in Patients With Coronary Artery Disease
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Background: Prasugrel is associated with higher levels of platelet inhibition compared
to clopidogrel, which may result in longer times for platelet P2Y12 receptor function
to recover following drug cessation. The aim of this study was to assess the time to
recovery of platelet function in patients with coronary artery disease following
administration of a prasugrel or clopidogrel loading dose (LD).
Methods: Recovery of platelet function after LD was defined as occurring on the first
day that VerifyNow™ P2Y12 reaction units (PRU) were ≤60 below pre-drug values
and remained in this range. The percentage of subjects (n=21) who recovered over
time (3, 5, 7, 9, and 11 days) following 30 or 60 mg prasugrel or 600 mg clopidogrel
with aspirin was assessed by measurement of PRU. The relationship between inhibition
of platelet function at 24 hours post LD to time of recovery was also evaluated.
Results: Pre-drug, mean PRU was 337.6, 308.2, and 323.0 for prasugrel 60 mg,
prasugrel 30 mg, and clopidogrel 600 mg, respectively. At 24 hours post-LD, mean
PRU were lowest for prasugrel 60 mg (32.5), followed by prasugrel 30 mg (70.0), and
clopidogrel 600 mg (193.0). Recovery for all prasugrel-treated subjects occurred from
Days 5-9, while recovery for clopidogrel-treated subjects occurred from Days 3-7
(Figure 1).
Conclusion: Time for platelet function to return to baseline reflected the extent of
platelet inhibition at 24 hours post-LD. Prasugrel-treated subjects required a longer
time for recovery compared with clopidogrel.
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High On-treatment Platelet Reactivity Measured by Various Platelet Function
Tests: Is the Current VASP-PRI Cutoff Too Low?
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Hwang2, Paul A. Gurbel1
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Background: High on-treatment platelet reactivity (HPR) to ADP measured by
multiple methods has been linked to adverse post-PCI clinical event occurrence. The
correlation of HPR cutoffs is still a matter of debate, since the predictive value and
HPR group size are different depending on platelet function assays. To determine the
comparable cutpoint, we correlated cutpoints for HPR determined by various assays
in the same patient cohort.
Methods: Platelet measures [5μM ADP-induced light transmission aggregation
(LTA:5μMADP); P2Y12 reaction units by VerifyNow (PRU), and platelet reactivity
index by VASP assay (PRI)] were evaluated (n=936 pairs, cohort I) in stable CAD
patients during P2Y12 receptor inhibitor treatment. These assays also performed in
PCI-treated patients receiving standard aspirin and clopidogrel therapy (n=584, cohort
II). The HPR cutpoints were defined as LTA:5μMADP >46%, PRU >235, and PRI
>50%.
Results: In the stable CAD patients, LTA:5μMADP showed significant correlations
with PRU and PRI (r ≥0.688). In ROC curve analysis using the cutpoint of
LTA:5μMADP (>46%), the matched values of PRU and PRI were >234 (AUC 0.943,
p<0.001, sensitivity 87.3% and specificity 87.8%) and >60% (Figure A). Among PCI-
treated patients, the prevalence of HPR was highest based on PRI >50% (69%)
compared with other criteria (≤55%). The comparable values for LTA:5μMADP >46%
were PRU >235 (AUC 0.850, p<0.001, sensitivity 85.3% and specificity 70.4%) and
PRI >59% (Figure B).
Conclusion: The published cutoff values for HPR by LTA:5μMADP and PRU were
well correlated, whereas published PRI >50% cutoff value may overestimate the risk
of HPR. Updated cutoff of PRI > 60% may better stratify the risk for HPR and can be
used in future trials.
TCT-161
Anemia is a major predictor of decreased platelet response to clopidogrel
following coronary stenting
Catalin Toma, Firas E Zahr, Diego Moguillansky, Nicole Lemieux, Roy Semaan,
Rosalyn J Rapsinski, Joon S Lee, Suresh Mulukutla, Oscar C Marroquin
University of Pittsburgh Medical Center, Pittsburgh, PA
Background: A decreased response to clopidogrel as assessed by platelet aggregation
testing following percutaneous coronary interventions (PCI) is a predictor of recurrent
ischemic events. Significant intra-individual variability in platelet aggregation on repeat
testing has been reported.
Methods: To understand this variability, we examined the clinical and laboratory
elements linked to high residual platelet reactivity (HRPR) in 255 consecutive patients
tested at least 12 hrs following the PCI, using both light transmission aggregometry in
response to 5μM ADP (LTA) and the Accumetrics VerifyNow P2Y12 assay
(VNP2Y12). HRPR was defined based on previously validated cutoffs (>46% for LTA,
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